1

¹**Comparative and Integrated Analysis of Plasma Extracellular Vesicles Isolations**

²**Methods in Healthy Volunteers and Patients Following Myocardial Infarction**

- ³**Short title:** Integrated Analysis of Plasma Extracellular Isolation Methods
- 4 Daan Paget^{1,2}, Antonio Checa³, Benedikt Zöhrer^{4,5}, Raphael Heilig⁶, Mayooran
- 5 Shanmuganathan^{1,7}, Raman Dhaliwal⁸, Errin Johnson⁸, Maléne Møller Jørgensen^{9,10}, Rikke
- 6 Bæk⁹, Oxford Acute Myocardial Infarction Study (OxAMI)^{1,7}, Craig E. Wheelock^{3,5,11}, Keith M.
- 7 Channon^{1,7}, Roman Fischer⁶, Daniel C. Anthony², Robin P. Choudhury^{1,7} and Naveed
- 8 Akbar¹.
- ¹ Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
0 Oxford Oxford United-Kingdom 10 Oxford, Oxford, United Kingdom.
11 ² Department of Pharmacology. I
- ² Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
12. ³ Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karoli
- ³ Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute,
13. Stockholm Sweden 13 Stockholm, Sweden.
14 ⁴ Respiratory Medic
- 4 ⁴ Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular
15 Medicine Karolinska Institutet Stockholm Sweden. 15 Medicine, Karolinska Institutet, Stockholm, Sweden.
16 ⁵ Department of Respiratory Medicine and Al
- 5 ⁵ Department of Respiratory Medicine and Allergy, Karolinska University Hospital,
17 Stockholm Sweden. 17 Stockholm, Sweden.
18 ⁶ Target Discovery
- ⁶ Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of 19
19 Medicine University of Oxford Oxford United Kingdom 19 Medicine, University of Oxford, Oxford, United Kingdom.
20 ⁷ Acute Vascular Imaging Centre, Radcliffe Department o
- 20⁷ Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of
21 Oxford United Kingdom
- 21 Oxford, United Kingdom.
22 ⁸ Sir William Dunn Schoo
- ⁸ Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
23 ⁹ Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.
- ⁹ Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.
24. ¹⁰ Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- ¹⁰ Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
25. ¹¹ Gunma University Initiative for Advanced Research (GIAR), Gunma L
- 25 ^{- 11} Gunma University Initiative for Advanced Research (GIAR), Gunma University, Showa-
26 machi Maebashi Gunma, Japan 26 machi, Maebashi, Gunma, Japan.
27
-

²⁸**Word Count: 11,258**

- ²⁹**Number of Figures: 8**
- ³⁰***Corresponding Author:** Dr Naveed Akbar
- ³¹**E-mail:** Naveed.Akbar@cardiov.ox.ac.uk
- 32 Telephone Number: 01865 234902
- ³³Address: Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John
- 34 Radcliffe Hospital, Level 6, West Wing, OX3 9DU, United Kingdom.

35.

36

³⁷**Abstract**

38 Plasma extracellular vesicle (EV) number and composition are altered following myocardial 39 infarction (MI), but to properly understand the significance of these changes it is essential to 40 appreciate how the different isolation methods affect EV characteristics, proteome and 41 sphingolipidome. Here, we compared plasma EV isolated from platelet-poor plasma from 42 four healthy donors and six MI patients at presentation and 1-month post-MI using 43 ultracentrifugation, polyethylene glycol precipitation, acoustic trapping, size-exclusion 44 chromatography (SEC) or immunoaffinity capture. The isolated EV were evaluated by 45 Nanoparticle Tracking Analysis, Western blot, transmission electron microscopy, an EV-46 protein array, untargeted proteomics (LC-MS/MS) and targeted sphingolipidomics (LC-⁴⁷MS/MS). The application of the five different plasma EV isolation methods in patients 48 presenting with MI showed that the choice of plasma EV isolation method influenced the 49 ability to distinguish elevations in plasma EV concentration following MI, enrichment of EV-50 cargo (EV-proteins and sphingolipidomics) and associations with the size of the infarct 51 determined by cardiac magnetic resonance imaging 6 months-post-MI. Despite the selection 52 bias imposed by each method, a core of EV associated proteins and lipids was detectable 53 using all approaches. However, this study highlights how each isolation method comes with 54 its own idiosyncrasies and makes the comparison of data acquired by different techniques in 55 clinical studies problematic.

56

⁵⁷**Key words**

58 Ultracentrifugation, size exclusion chromatography, precipitation, acoustic trapping, 59 immunoaffinity capture, plasma, omics, human.

3

⁶¹**Introduction**

62 Plasma extracellular vesicles (EV) are increased in number and carry altered protein, lipid 63 and RNA cargo in the peripheral blood in many pathologies [1-6]. Analysis of plasma EV by 64 omics approaches may provide unparalleled insight into multiple disease mechanisms and 65 disease monitoring in patients for personalized medicine. However, it is unclear how different 66 plasma EV isolation methods influence the plasma EV-profile or the so-called 'EV-signature' 67 in patients.

68

⁶⁹Current methods for the isolation of heterogeneous plasma EV include: ultracentrifugation ⁷⁰(UC), density ultracentrifugation, field-flow fractionation, size-exclusion chromatography ⁷¹(SEC), precipitation, acoustic trapping [7] and immunoaffinity capture [8]. However, 72 unsurprisingly, laborious protocols that yield pure EV from plasma are less well favoured in 73 large cohorts [9, 10] than protocols that are easier, lower cost, and more convenient. These ⁷⁴methodological predilections are further impacted by the availability of stored biobank 75 plasma, which often carry contaminating erythrocytes, immune cells, and platelets [11]. ⁷⁶Irrespective of pre-storage processing, all plasma is a rich source of lipoproteins ⁷⁷(apolipoprotein A and B), albumin, globulins and fibrinogens, which can co-isolate with 78 plasma EV. The proportion of these cell-derived and non-cellular contaminants in the purified 79 sample is method-dependent [12] and they may obscure EV associated cargo [13, 14].

80

81 Comparative isolation studies for plasma EV often assess EV size and concentration by 82 Nanoparticle Tracking Analysis (NTA) and morphology by transmission electron microscopy 83 (TEM). EV markers are usually evaluated using western blot or flow cytometry [15-18]. ⁸⁴These standard analyses are often driven by the requirements of scientific bodies and 85 consensus statements, which might be considered too prescriptive and refractory to change 86 as our understanding of EV biology evolves [14]. However, additional assessments of how 87 isolation methods influence the plasma EV preparation have been explored with a range of 88 techniques, including proteomics [16, 18-21], profiling of cytokines [22], RNA integrity [23,

4

89 24], lipidomics [25], flow cytometry [15, 26] or a combination of these methods [16]. ⁹⁰However, the wide range of plasma EV isolation and characterization techniques has 91 evolved largely in the absence of systematic method characterization comparisons. As a 92 consequence, the absence of an understanding of the impact of isolation techniques has led 93 to plenty of uncertainty in relation to the interpretation of EV discoveries in clinical samples.

⁹⁵Here, we used platelet-free plasma from the same healthy volunteers to compare five 96 different plasma EV isolation methods including: UC, precipitation, acoustic trapping, SEC ⁹⁷and immunoaffinity capture using tetraspanins CD9, CD63 and CD81 (**Figure 1**)**.** We then 98 sought to determine how plasma EV isolation methods influence EV characteristics in a set 99 of clinically well characterised individuals. Acute myocardial infarction (MI) is an important 100 pathology; it is also an example of sterile inflammation where plasma EV number and 101 composition are acutely altered [5, 6]. Plasma EV from MI patients at two different time 102 points were isolated using the five different EV isolation methods (Figure 1). Integrated 103 unsupervised analysis of all the acquired characterization data from the five different ¹⁰⁴methods was used to identify the similarities and differences between each method and to 105 highlight how each technique might influence the protein and sphingolipid composition.

5

¹⁰⁶**Materials and Methods**

107 Healthy Volunteers and Acute Myocardial Infarction Patients.

¹⁰⁸All human investigations were conducted in accordance with the Declaration of Helsinki. The 109 Oxfordshire Research Ethics Committee (Ref: 08/H0603/41 and 11/SC/0397) approved the 110 human clinical protocols. All healthy volunteers and myocardial Infarction (MI) patients 111 provided informed written consent for inclusion in the study.

-

113 Generation of Platelet Poor Plasma

114 Platelet-poor plasma was generated from healthy volunteers (N=4), patients presenting with ¹¹⁵MI (N=6) and from the same patients 1-month post-MI. 10-20 mL of whole blood was 116 collected in EDTA (Greiner Bio-One, Stonehouse, United Kingdom) coated tubes and 117 centrifuged at 1,000 x g for 25 minutes. The plasma was collected and centrifuged again for 118 10 minutes at 5,000 x g to produce platelet-poor plasma. The platelet-poor plasma was 119 stored in 500 μ L aliquots at -80 °C for future use.

120

121 **Isolation of plasma EV using UC**

122 Plasma aliquots were thawed at room temperature and EV were isolated by UC by 123 transferring 500 µL of platelet-poor plasma from healthy volunteers or 100 µL from platelet-124 poor plasma from MI patients to a 13.2 mL QuickSeal tube (Beckman Coulter, California, 125 United States). The tubes were filled with a 16 G hypodermic needles (Microlance, VWR, 126 Pennsylvania, United States) fitted to a 10 mL syringe (VWR, Pennsylvania, United States) 127 and after plasma was injected into the tube, 13 mL of phosphate buffered saline (PBS, 128 Thermo Fischer Scientific, Massachusetts, United States) was added. The tubes were 129 sealed using a soldering iron (Zacro, 60 W) and centrifuged using an Optima MAX-XP ¹³⁰ultracentrifuge (Beckman Coulter, California, United States) at 120,000 x *g* for 120 minutes 131 at 4 °C with a MLA55 fixed-angle rotor (Beckman Coulter, California, United States) [5, 6]. 132 The pelleted plasma EV were resuspended in 100 µL PBS or RIPA buffer (Thermo Fischer 133 Scientific, Massachusetts, United States) for subsequent analysis.

134

135 Isolation of plasma EV using precipitation

136 Plasma EV were isolated by precipitation by using the Total Exosome Isolation Kit ¹³⁷(Invitrogen, Massachusetts, United States). 500 µL of platelet-poor plasma from healthy 138 volunteers or 100 μ L of platelet-poor plasma from MI patients was thawed at room 139 temperature. After vortexing, 20-100 μL of the Exosome Precipitation Reagent (Total ¹⁴⁰Exosome Isolation Kit (for plasma), ThermoFisher Scientific, Massachusetts, United States) ¹⁴¹was added and mixed by repeated pipetting. Samples were incubated for 30 minutes on ice, 142 the mixture was centrifuged at 10,000 x *g* for 10 minutes by a Haraeus Fresco 17 benchtop 143 centrifuge (ThermoFisher Scientific, ibid) at room temperature. The supernatant was 144 removed and samples were centrifuged again at 2,000 x *g* for 2 minutes to remove residual 145 supernatant. The pelleted plasma EV were resuspended in 100 µL PBS or RIPA buffer for 146 downstream analysis by repeated pipetting.

147
1

148 **Isolation of plasma EV using acoustic trapping**

149 Acoustic trapping of plasma for the isolation of EV was achieved by diluting plasma 1:1 with 150 PBS as previously described [18]. Briefly, samples were loaded onto a Costar 96-well plate ¹⁵¹(Corning, New York, United States) and inserted in the AcouSort device (Version 2.0) ¹⁵²(AcouSort AB, Lund, Sweden). Acoustic waves were produced by a waveform generator ¹⁵³(Keysight 33210A, Keysight, California, United States) with a 9.2 V output and were directed 154 into a borosilicate capillary acoustic trapping unit (AcouSort AB, Lund, Sweden). Following 155 activation of the waveform generator and the acoustic trapping unit was initialised, 50 μL of ¹⁵⁶12 μm polystyrene beads (AcouSort AB, Lund, Sweden) were loaded into the acoustic 157 trapping unit using a syringe pump (Tricontinent C2400 (Tricontinent, Fürstenfeldbruck, 158 Germany) set to 50 μL/min. Each run consisted of 100 μL of 1:1 diluted plasma and were 159 loaded with a syringe pump speed of 20 μL/min. After acoustic trapping, the samples were 160 washed by aspirating 15 μL of PBS at 20 μL/min and dispensing 50 μL at 20 μL/min. After 161 the PBS wash, the samples were eluted in 50 μL of PBS and used for downstream analysis.

7

163 Isolation of plasma EV using size exclusion chromatography

164 Size exclusion chromatography (SEC) isolation of plasma EV was achieved by using the ¹⁶⁵Exo-spin™ 96 (Cell Guidance Systems, Missouri, United States) [27]. Columns were 166 equilibrated at room temperature for 15 minutes prior use. Afterwards, the columns were 167 washed twice with 250 μL of PBS. Plasma was thawed at room temperature and 100 μL of 168 plasma from healthy volunteers or MI patients was loaded into each column. Plasma EV 169 were eluted by adding 200 μL of PBS to the top of the column eluted under gravity. Plasma 170 EV were collected and stored for subsequent analysis.

172 Isolation of plasma EV using immunoaffinity capture

173 Prior to isolation, the plasma was passed through a SEC method as described above. ¹⁷⁴Exosome-Human CD9 Isolation Reagent, Exosome-Human CD63 Isolation/Detection 175 Reagent and Exosome-Human CD81 Isolation Reagent (all Invitrogen, Massachusetts, 176 United States) were used to capture plasma EV. The mixture was created by resuspending ¹⁷⁷each bead solution and mixing by repeated pipetting. Control IgG-isotype (10400C, Thermo 178 Fischer Scientific, Massachusetts, United States) matched beads were conjugated according 179 to the instructions of the Dynabeads Antibody Coupling Kit (Invitrogen, Massachusetts, ¹⁸⁰United States). After SEC pre-isolation, the samples were incubated with 80 μL of the 181 combined CD9, CD63 and CD81 beads (end concentration 1 x 10^7 / mL, equal quantity of 182 each bead mixture) or equally concentrated IgG control beads at 4 $^{\circ}$ C for 18 hours under 183 continual rotation by a vertical rotor (Grant Bio, Essex, United Kingdom). After incubation, 184 the beads were pelleted for 5 minutes at room temperature using a Dynal Magnet ¹⁸⁵(Invitrogen, Massachusetts, United States) and the supernatant was collected for 186 subsequent analysis. Following pelleting, the samples were washed three times with 200 µL 187 of PBS and magnetic beads were pelleted as described above. Following the washes, the 188 beads were resuspended in RIPA buffer and supernatant was separated by using a 2,000 x ¹⁸⁹*g* spin and collected for subsequent analysis.

> 8 8

191

192 Nanoparticle Tracking Analysis

193 Plasma EV size distribution and concentration were determined by Nanoparticle Tracking ¹⁹⁴Analysis (NTA) using a Zetaview device (Particle Metrix, Inning am Ammersee, Germany) as 195 previously described [5, 6]. Prior to injection into the sample chamber, samples were diluted 196 in PBS. The Zetaview measured the sample chamber from 11 positions in 2 cycles. The 197 settings were set at sensitivity 80, fame 30 and shutter speed 100. Silica 100-nm ¹⁹⁸microspheres (Polysciences Inc., Philadelphia, United States) were used to quality check the 199 instrument performance routinely. The particle concentration per method was calculated as 200 the change (Δ) compared to the the control sample, in which PBS replaced the plasma 201 sample.

203 Protein concentration

²⁰⁴Protein concentration was determined by bicinchoninic assay (BCA) (Thermo Fischer 205 Scientific, Massachusetts, United States). A standard curve with Bovine Serum Albumin ²⁰⁶(Thermo Fischer Scientific, Massachusetts, United States) was used to calculate the protein 207 concentration. Isolated EV were diluted 1:2 or 1:6 with RIPA buffer and needle sonicated by ²⁰⁸a SonoPuls HD2070 (Bandelin, Berlin, Germany) at 40% power for 10 seconds. 25 μL of ²⁰⁹sonicated sample or standard was incubated in duplicate with 175 μL of a 25:1 ratio between 210 Reagent A and Reagent B (Thermo Fischer Scientific, Massachusetts, United States) and 211 incubated at 37 °C for 30 minutes. After incubation, absorbance was measured at 562 nm 212 using a plate reader (FLUOstar Omega plate reader, BMG Labtech, Aylesbury, United 213 Kingdom).

214

215 Transmission Electron Microscopy

216 Transmission electron microscopy (TEM) of the isolated EV was conducted as previously 217 described [6]. Briefly, grids (300 mesh Cu carbon film) were glow discharged for 20 seconds

> 9 9

218 at 15 mA (Leica EM ACE 200). The isolated plasma EV samples were added to the grid for 2 219 minutes, blotted, stained with 2% uranyl acetate for 20 seconds, blotted and allowed to air 220 dry. Images were acquired on a 120 kV Tecnai 12 TEM (Thermo Fischer Scientific, ²²¹Massachusetts, United States) equipped with a OneView digital camera (Gatan, California, 222 United States). TEM images of control samples, in which the isolation method was run with 223 PBS in the place of the plasma, were obtained for each method. Immunoaffinity-based 224 isolated EV were fixed with 1.6% glutaraldehyde in PBS for 1 hour at 4 \degree C. Following 225 fixation, the beads were fixed in 4% agarose with PBS. The agarose was cut into small 226 cubes (1-2 mm3). Sections were collected onto 200 mesh Cu grids and imaged using a 227 Gatan OneView camera with a FEI Tecnai 12 TEM at 120kV.

228

229 Proteomics

230 Isolated plasma EV were processed for proteomics as previously described [28, 29]. In 231 short, the samples were reduced in 5 mM dithiothreitol for 30 minutes at room temperature. 232 Subsequently, the samples were alkylated with 20 mM iodacetamide for 30 minutes and 233 precipitation using chloroform-methanol precipitation. Quantified protein groups with -≥2 234 unique peptides were included in the comparison of proteomes. The LFQ values for each 235 protein group was deducted by the LFQ from control samples per isolation method. Protein 236 abundance was normalised by Log-transformation. Gene Ontology (GO) analysis of the 237 protein groups [30] was conducted by using Genontology.org [30] and the data were 238 extracted on 19-07-2021. P-values were corrected for false discovery rate (FDR) and 239 significance was set at $p<0.05$. Fisher exact tests were conducted using R on published 240 databases EVpedia [31], Vesiclepedia [32] and Exocarta [33].

242 EV-Array

243 Isolated plasma EV were analysed by a targeted EV-Array, which has been described 244 previously [6, 34]. In short, a protein microarray plate was generated with the following 245 antibodies: CD146 (P1H12), Flotillin-1, TSG101 (Abnova, Taiwan), CD9, CD81 (Ancell

10

246 corporation, Minnesota, United States); CD16 (3G8, BD Biosciences, California, United ²⁴⁷States); Alix (3A9), VEGFR2 (7D4-6; Biolegend, California, United States); CD63 (Bio-Rad, ²⁴⁸California, United States); ICAM-1 (R6.5, eBioscience, California, United States); Endoglin ²⁴⁹(LSbio, Washington, United States); Tissue factor (323,514), VCAM-1 (HAE-2Z), 250 Thrombomodulin (501733), CD31 (AF806, R&D Systems, Minnesota, United States), VE-251 Cadherin (AF938, R&D Systems, Minnesota, United States). After blocking with the blocking 252 buffer (50 mM ethanolamine, 100 mM Tris, 0.1% SDS, pH 9.0) for 30 minutes, the wells 253 were emptied, and the plate was dried for 5 hours and sealed. The samples were incubated 254 in the antibody coated microarray plate overnight at 2-8 $^{\circ}$ C. Following a wash, each well was 255 incubated with a 100 µL of a detection antibody cocktail (biotinylated anti-human-CD9, -256 CD63 and -CD81 (Ancell, Minnesota, United States). After another wash, 100 µL 257 streptavidin-Cy3 Life Technologies, Massachusetts, United States) diluted 1:3,000 was 258 added to each well and incubated for 30 minutes. The plate was scanned using a 259 sciREADER FL2 microarray scanner (Scienion AG, Berlin, Germany), at 535 nm and an 260 exposure time of 2,000 milliseconds. For each protein the control, PBS sample value was 261 subtracted from the result.

263 Western blot

264 Isolated plasma EV or controls were lysed using RIPA buffer with protease and phosphatase 265 inhibitors PhosSTOP (Roche, Basel, Switzerland) and cOmplete (Roche, Basel, Switzerland) 266 and were needle sonicated by a SonoPuls HD2070 (Bandelin, Berlin, Germany) at 40% 267 power for 10 seconds as previously described [5, 6]. Following sonication, samples were 268 incubated at 95 °C for 5 minutes to reduce. 8 µg of protein was combined with NuPage LDS 269 sample buffer (4x) agent (Invitrogen, Massachusetts, United States). The samples were 270 loaded onto a 4-12% bis-tris gradient gel (NuPAGE 4-12% Bis-Tris Protein Gel; 1.5 mm 271 (ThermoFisher Scientific, Massachusetts, United States) with Amersham ECL Full Range 272 ladder (Cytiva Life Sciences, Massachusetts, United States). Separated samples were 273 transferred to a nitrocellulose membrane (Amersham Proton 0.2 μm, GE Healthcare, Illinois,

11

²⁷⁴United States) and blocked for non-specific binding in 5 % skimmed milk powder (Marvel 275 Original, New York, United States) in 0.5% PBS-tween 20 (Sigma-Aldrich, Missouri, United 276 States) for 1 hour. Membranes were incubated with primary antibodies overnight: ALIX ²⁷⁷(ab117600, Abcam, Cambridge, United Kingdom) (1/1,000 dilution), CD63 (EXOAB-KIT-1, 278 System Biosciences, California, United States) (1/1,000 dilution), ApoB (Ab139401, Abcam, ²⁷⁹Cambridge, United Kingdom) (1/20,000 dilution), albumin (MAB1455, R&D Systems, ²⁸⁰Minneapolis, Canada) (1/8,000 dilution), ApoA-I (Mab36641, R&D systems, Minneapolis, ²⁸¹Canada) (1/8,000 dilution) and H3 (D1H2, Cell Signalling Technology, Massachusetts, 282 United States) (1/1,000 dilution) 5 % milk in PBS-tween (PBS-T). Membranes were washed 283 three times with PBS-T and incubated with secondary-horse radish peroxidase (HRP) 284 conjugated antibodies (1/20,000 α-mouse W402B or 1/50,000 α-rabbit W401B, Promega, ²⁸⁵Wisconsin, United States) for 1 hour. The membranes were washed once again with PBS-T 286 before incubating them with enhance chemiluminescence substrate (Pierce ECL, 287 ThermoFisher Scientific, Massachusetts, United States) for imaging (Bio-Rad ChemiDoc MP 288 Imaging system, California, United States).

290 Sphingolipidomics

²⁹¹Sphingolipids were determined as previously described [35]. 25 μL of each sample were ²⁹²combined with 10 μL solution containing labelled sphingolipid internal standards in LC-MS ²⁹³Methanol (Honeywell, North Carolina, United States) was added to each sample. This was 294 followed by the addition of 100 μL of methanol to each sample. Samples were then vortexed 295 for 30 seconds and sonicated for 15 minutes in a Fisherbrand Ultrasound bath S60 (Fischer-296 Scientific, Massachusetts, United States) with ice. Next, samples were centrifuged at 12,000 297 x *g* during 15 minutes at 6□C. Finally, 80 μL of the supernatant were transferred to an LC-²⁹⁸MS amber vial (Waters, Wilmslow, United Kingdom) equipped with a 150 μL insert. Samples 299 were randomized by time point of the individual within an extraction method. Samples were 300 analyzed on an Acquity UPLC coupled to a Xevo TQ-S Mass Spectrometer (Waters, 301 Wilmslow, United Kingdom) as previously described.

303 Bioinformatics and Integrated analysis

304 Integrated analysis was conducted by combining data from the NTA, protein concentration, ³⁰⁵EV-Array, proteomic and sphingolipidomic analysis. The data was normalized per row and 306 log transformed. Following data normalization, a principal component analysis was ³⁰⁷conducted in R 4.0.0 [37] using the *factoextra* [38] and *FactoMineR* [39] packages. For 308 visualization *ggplot2* [40] was used. Each of the principal components were then used to 309 create a heatmap by extracting the values from the eigenvalues for each of the principal 310 components and processing them in *pheatmap* [41]. The data was clustered by using double 311 hierarchical clustering using the *pheatmap* R package.

312

313 Data availability

³¹⁴All data produced in the present study are available upon reasonable request to the 315 Corresponding Author.

316

317 Statistical analysis

³¹⁸Data was plotted as mean with standard deviation. Normality of the data was confirmed 319 using QQ plot and D'Agostino-Pearson normality test. For paired analysis, at the two time 320 points, or for two independent groups, paired or unpaired Students T-test were used 321 respectively (GraphPad Prism 9). Correlation analysis was carried out using linear Pearson 322 regression analysis (Graphpad Prism 9). One-way ANOVA with Bonferroni correction post-323 hoc tests were used for analyses with >3 independent groups. The proteomic and lipidomic 324 data was analyzed using a Kruskal-Wallis statistical test with Bonferroni post-hoc tests. p 325 values <0.05 were considered significant.

³²⁶**Results**

327 Plasma EV number and size is influenced by the isolation method

³²⁸The concentration of isolated EV (expressed as delta over a matched PBS or and IgG 329 control sample) determined by NTA differed per method (UC 9.5 x 10⁹ ± 1.8 x 10⁹ EV / mL, 330 precipitation 6.1 x 10¹¹ ± 2.7 x 10¹¹ EV / mL, acoustic trapping 6.4 x 10⁹ ± 2.8 x 10⁹ EV / mL, 331 SEC 5.5 x 10⁹ ± 1.9 x 10⁹ EV / mL and immunoaffinity 2.8 x 10¹⁰ ± 7.1 x 10⁹ EV / mL, **Figure** ³³²**2A**). In agreement with previously published studies, precipitation yielded significantly higher 333 numbers of particles / mL compared to UC [15, 36] and SEC [15, 37] (both p<0.01). Plasma ³³⁴EV number, isolated by precipitation, were also higher than the concentration acquired by 335 acoustic trapping or by immunoaffinity capture (both p<0.01) (**Figure 2A**). The size and 336 concentration distribution for each biological replicate exhibited uniformity within each 337 isolation method and the different isolation methods did give a similar size distribution profile 338 overall, which ranged from 15 nm (**Figure 2B)**. However, the mean size of EV isolated by 339 UC was significantly higher compared to the other methods (UC 143.7 \pm 3.4 nm, versus 340 precipitation 94.2 \pm 3.9 nm, acoustic trapping 81.2 \pm 3.9 and SEC 87.2 \pm 1.5, p<0.01 all) ³⁴¹(**Table 1**).

343 Plasma EV protein concentration

³⁴⁴The protein concentration (expressed as the change over a matched PBS or and IgG 345 control) also differed across the EV isolation methods: UC 982 \pm 113 µg / mL, precipitation 346 9,478 \pm 3,174 µg / mL, acoustic trapping 1,211 \pm 141 µg / mL, SEC 382 \pm 51 µg / mL and 347 immunoaffinity 33 \pm 12 µg / mL (**Figure 2C)**. EV generated by precipitation had a 348 significantly higher protein concentration compared to UC, acoustic trapping, SEC or 349 immunoaffinity (all p<0.01, **Figure 2C**). The purity of EV isolation can be estimated by 350 calculating a ratio of EV number (EV / mL) to protein concentration (μ g / mL) [44]. The EV 351 purity ratio differed between isolation method: UC 9.0 x 10⁶ ± 1.4 x 10⁶; precipitation 4.7 x 352 10⁸ ± 1.5 x 10⁸; acoustic trapping 2.1 x 10⁷ ± 7.6 x 10⁶; SEC 6.8 x 10⁶ ± 4.0 x 10⁶ and 353 immunoaffinity capture 3.1 x 10⁸ \pm 1.0 x 10⁸. Both the immunoaffinity and precipitation

14

354 methods achieved a significantly higher EV purity ratio when compared to UC, SEC or ³⁵⁵acoustic trapping (p<0.01 compared to all methods) (**Supplemental Figure 1**).

357 Plasma EV protein characterisation by Western blot

358 As NTA is unable to distinguish between plasma EV and similarly sized protein aggregates 359 and lipoproteins, we analysed the isolated plasma EV obtained from each method for a 360 number of markers by western blotting. ALIX and CD63 were included as the EV markers. 361 For the plasma lipoprotein contaminants, we measured ApoB and ApoA-I. Histone H3 for 362 cellular contaminant by western blot and albumin was also included in the set. Each isolation ³⁶³method showed the presence of EV markers ALIX and CD63 **(Figure 2D**). Apolipoproteins ³⁶⁴(ApoA-I and ApoB) were also present in all isolation methods. All methods were negative for 365 markers of cellular contamination by histone H3. Surprisingly, the IgG isotype control for 366 immunoaffinity capture using CD9, CD63 and CD81 also showed the presence of EV 367 markers ALIX, CD63 and ApoB, albumin, ApoA-I but histone H3 was absent **(Figure 2D)**.

368

369 Plasma EV morphology by TEM

370 To determine the morphology of isolated plasma EV, we undertook TEM for the five different 371 plasma EV isolation methods versus a matched PBS control or an IgG control for 372 immunoaffinity capture beads. TEM analysis showed EV-like particles for each isolation ³⁷³method and an absence of EV-like particles in their respective PBS isolation controls ³⁷⁴(**Figure 2E-H**). Immunoaffinity beads CD9, CD63 and CD81 were embedded in agar and 375 sectioned to visualise the bead surface for EV-like structures versus the IgG control. IgG 376 control showed no EV-like particles present (Figure 2I). Immunoaffinity capture using CD9, ³⁷⁷CD63 and CD81 beads showed intact EV-like particles captured on the bead surface ³⁷⁸(**Figure 2J)**.

379

380 Plasma EV compositional analysis using a high throughput protein EV-Array

15

381 The results detailed above provide evidence for the relative success of each method to yield 382 plasma EV and assessment of relative plasma EV purity [39]. However, these techniques do 383 not readily distinguish the abundance of specific plasma EV populations carrying, for 384 instance, specific cell-associated markers, or easily allow quantitative assessment of the 385 abundance of contaminating lipoproteins. Thus, we probed the composition of the plasma ³⁸⁶EV isolated from each method for general EV markers CD9, CD63, CD81, ALIX, TSG101, 387 Flotillin 1, Annexin V and a panel of 18 cell associated markers, which may distinguishes EV 388 from platelets, endothelial cells, immune cells, muscle and lipoprotein contaminants 389 apolipoprotein E (ApoE) and apolipoprotein H (ApoH) using a validated high throughput EV-390 protein antibody array (**Figure 3**) [34]. We utilised a matched PBS control for UC, 391 precipitation, acoustic trapping and SEC and an IgG control for immunoaffinity capture. For 392 the EV-associated proteins, CD9 and CD81, they were significantly higher in plasma EV 393 isolated by UC compared to the other methods ($p<0.01$ for both). Annexin V was significantly 394 higher in the acoustic trapping samples compared to SEC and immunoaffinity capture ³⁹⁵(p<0.01 and p<0.05, respectively).

³⁹⁷Hierarchical clustering of the EV-Array acquired data for the different isolation methods 398 indicates that there are significant method-dependent differences for cell associated EV ³⁹⁹markers (**Figure 3**). CD31 was significantly higher in precipitation isolated plasma EV versus 400 acoustic trapping ($p<0.05$). CD41 was significantly higher in UC isolated plasma EV 401 compared to precipitation isolated EV (p<0.05) and CD16 content was significantly higher in 402 the precipitation isolated plasma EV samples compared to SEC (p <0.01). There were no 403 differences between immunoaffinity capture using CD9, CD63 and CD81 and IgG controls ⁴⁰⁴(**Figure 3)**.

406

407 Unbiased proteomic analysis of plasma EV

16

408 We next determined the proteomic profile of each isolation method using unbiased LC-⁴⁰⁹MS/MS versus their respective PBS or IgG controls for each method. The proteomic profile 410 following plasma EV isolation showed a significantly higher number of quantified protein 411 groups compared to their respective controls for all isolation methods, except immunoaffinity 412 capture, which displayed similar results to the IgG control beads (UC p<0.01, precipitation ⁴¹³p<0.05, acoustic trapping p<0.01 and SEC p<0.01, **Figure 4A**). The choice of plasma EV 414 isolation method influenced the overall EV-proteome, but nine protein groups were common ⁴¹⁵across all methods (**Supplemental Figure 2**). These were: immunoglobulin heavy constant 416 gamma 1, alpha-2-macroglobulin, haptoglobin, immunoglobulin heavy constant µ, 417 immunoglobulin kappa constant, serpin family A member 1, albumin, fibrinogen alpha chain 418 and Apo-A1.

419

⁴²⁰We used hierarchical clustering of the top 30 quantified protein groups across the different 421 plasma EV isolation methods and found a distinct separation between isolation methods. UC 422 and SEC isolated plasma EV clustered together and precipitation, acoustic trapping and ⁴²³immunoaffinity capture formed a distinct separate cluster (**Figure 4B**). Hierarchical clustering 424 indicates that these differences between UC/SEC and precipitation, acoustic trapping and 425 immunoaffinity capture were driven by an abundance of protein groups with common plasma 426 proteins (ALB, A2M, ApoB, C3, TF, HP, Apo-A1, SERPINA1, CP and ITIH2), fibrinogens 427 (FGG and FGB) and immunoglobulins (IGHG1, IGKC, IGHG3, IGHM, IGK, IGHG2).

428

⁴²⁹To better understand the nature of the proteomic profile for each isolation method, we 430 conducted unbiased Gene Ontology (GO) pathway analysis of the protein groups associated 431 with each isolation method. All methods showed a significant association with EV pathways: ⁴³²Blood Microparticle GO: 0072562 and Extracellular Exosome GO:0070062 (all p<0.01, ⁴³³**Supplemental Figure 3A**). However, there was no clear separation between the different 434 isolation methods using this pathway analysis approach. To further scrutinize the EV 435 proteomic profile obtained per plasma EV isolation method we undertook a statistical

17

436 comparison using a Fisher's exact test with published EV-databases EVpedia [31], 437 Vesiclepedia [32] and Exocarta [33]. This determined the similarity between plasma EV 438 proteomic profiles obtained from the five different isolations methods to those published 439 previously by showing the size of the intersect. There was a significant overlap between the 440 five different isolation methods and the archived EV databases ($p<0.05$, all methods, ⁴⁴¹**Supplemental Figure 3B**). UC, SEC and immunoaffinity capture showed the greatest 442 similarity with published databases. Whereas precipitation and acoustic trapping showed 443 less similarity. Furthermore, we determined whether our plasma EV acquired proteomic 444 profiles from the five different methods were similar to previously published plasma EV 445 proteomic data for Exospin, SEC, ExoQuick, IZON35, IZON70, Optiprep and Exo-easy [16, 446 17] and found a significant overlap for all five plasma EV isolation methods ($p<0.01$) ⁴⁴⁷(**Supplemental Figure 4)**.

449 Targeted sphingolipidomic of plasma EV

⁴⁵⁰EV membranes are largely composed of lipids [46] and lipoproteins are a predominant 451 contaminant in plasma EV samples [41], which are influenced by the choice of isolation 452 method [12, 42]. We compared the lipidomic profile of the different plasma EV isolations ⁴⁵³methods by undertaking targeted sphingolipidomic analysis. The sphingolipidomic analysis 454 showed a significantly higher number of sphingolipids compared to the respective controls 455 for all isolation methods except immunoaffinity capture (UC $p<0.01$, precipitation $p<0.05$, 456 acoustic trapping p<0.01 and SEC p<0.01, Figure 5A). However, there were distinct 457 sphingolipidomic differences between the other methods. Eleven of the quantified 458 sphingolipids were common to all methods, which were DhCer(d18:0/24:0), Cer(d18:1/22:0), ⁴⁵⁹Cer(d18:1/24:1), Cer(d18:1/24_:0), SM(d18:1/16:0), SM(d18:1/18:0), SM(d18:1/24:1), ⁴⁶⁰SM(d18:1/24:0), HexCer(d18:1/16:0), HexCer(d18:1/24:1) and LacCer(d18:1/24:1) ⁴⁶¹(**Supplemental Figure 5**). Hierarchical clustering analysis of the sphingolipidomic profile for 462 each of the isolation methods showed that there are three distinct clusters (Figure 5B). ⁴⁶³Immunoaffinity capture and precipitation formed two separate individual clusters, whilst UC,

18

464 acoustic trapping and SEC clustered together. Hierarchical clustering indicates that these 465 group differences were driven by an abundance of sphingomyelins (16:0, 18:0, 24:0 and ⁴⁶⁶24:1), ceramides (22:0, 24:0 and 24:1), hexosylceramides (24:1) and lactosylceramides ⁴⁶⁷(16:0) in the precipitation group and a lack of these sphingolipids in the immunoaffinity 468 capture group.

470 Integrated comparison of plasma EV isolation methods

471 These data shows that plasma EV isolation methods have divergent impact on the yield of ⁴⁷²EV, their purity, the type of EV isolated from plasma that are associated with a particular cell 473 source and the overall proteomic and sphingolipidomic profile. To better understand how 474 these individual method associated differences influenced the plasma profile, we undertook 475 integrated analysis of all the different plasma EV isolation methods with all of the acquired 476 data. This included the EV particle concentration, protein concentration, EV-protein array 477 data, proteomic and sphingolipidomic data. To condense the multiple different variables, we 478 converted the data into principal components. Principal component analysis with two 479 components (PCA1 and PCA2) accounted for 47.2% of the variance and showed clear ⁴⁸⁰separation between the different isolation methods (**Figure 6A/B).** UC, SEC and 481 precipitation form distinct clusters, whereas acoustic trapping and immunoaffinity capture 482 clustered together. Specific principal component analysis indicated that the PCA1 is driven ⁴⁸³by proteomics acquired data and PCA2 is driven by sphingolipidomic data (**Supplementary** ⁴⁸⁴**Figure 6**). These integrated data show that the EV isolation method influences the omic and 485 integrated-based plasma EV-profile, which may influence interpretation of EV-acquired data 486 for clinical biomarker discovery and precision diagnostics.

488 Plasma EV isolation methods influence the diagnostic potential of plasma EV from patients 489 following MI

490 We next determined whether the choice of plasma EV isolation method impacts the ability to 491 detect changes in EV-profile in a disease state. We obtained plasma at time of presentation

19

492 with MI, but prior to percutaneous coronary intervention (PCI), and a matched control plasma 493 sample was obtained at 1-month post-MI from the same patients. The clinical patient ⁴⁹⁴characteristics are detailed in **Table 2**.

- 495
- 496
-

498 Plasma EV concentration in MI is influenced by the isolation method

⁴⁹⁹To mitigate any potential variability in bio-banked plasma samples we used three technical 500 plasma replicates per patient, per time point and per method. There were significantly more 501 plasma EV at time of presentation with MI versus the 1 month control follow up when plasma ⁵⁰²EV were isolated by UC, precipitation and acoustic trapping (p<0.05 for all) (**Figure 7A**), but 503 not by SEC and immunoaffinity capture (UC presentation: 2.8×10^9 EV / mL vs. UC follow-504 up: 2.1 x 10⁹ EV / mL; precipitation presentation: 1.5 x 10¹² EV / mL vs. precipitation follow-505 up: 7.9 x 10^{11} EV / mL; acoustic trapping presentation: 4.3 x 10^{10} EV / mL vs. acoustic 506 trapping follow-up: 1.9×10^{10} EV / mL; SEC presentation: 2.5×10^{11} EV / mL vs. SEC follow-507 up: 9.2×10^{10} EV / mL and immunoaffinity presentation: 2.0 x 10¹¹ EV / mL vs. 508 immunoaffinity capture follow-up: 9.8 x 10¹⁰ EV / mL, Figure 7A). The technical variance 509 between the three independent isolations from each patient, and at each time, point showed 510 that SEC gave significantly less variance compared to UC (10.0 \pm 3.1 % vs. 22.7 \pm 13.0 %, 511 p<0.01) (**Supplemental Figure 7A**). The mean plasma EV size was similar between the 512 time of presentation and 1 month follow up control for the five different plasma EV isolation ⁵¹³methods (**Supplemental Figure 7B**) and the size and concentration distribution profile 514 showed no distinct differences between time points or dependent on the plasma EV isolation ⁵¹⁵method (**Supplemental Figure 7C**).

517 The plasma EV isolation method influences plasma EV concentration association with infarct 518 **size**

20

⁵¹⁹We have previously reported that the total concentration of plasma EV in the peripheral 520 blood isolated by UC at the time of presentation correlates with the size of myocardial injury 521 and scar, determined by late gadolinium enhanced (LGE) MRI 6 months post-MI [5, 6]. ⁵²²Therefore, we determined whether plasma EV concentrations from the five different plasma ⁵²³EV isolation methods influenced the ability to determine this important clinical association. 524 Infarct size at 6-months post-MI significantly correlated with the plasma EV concentration at 525 time of presentation for UC samples $(R^2 = 0.89, p=0.02)$, but not for precipitation, acoustic 526 trapping, SEC or immunoaffinity capture (R²=0.10 p=0.60, R²=0.16 p=0.50, R²=0.05 p=0.71 527 and $R^2 = 0.10$, p=0.78, respectively) (**Figure 7B**).

529 Cell associated plasma EV are not influenced by the isolation method in MI

530 We determined whether the isolation methods influenced cell associated plasma EV-531 markers in MI patients at presentation versus the respective 1 month follow up sample. The 532 high through put EV-Array data was expressed as fold change over the matched follow-up 533 control samples per patient. Plasma EV markers were increased at time of presentation vs. 534 follow-up control (**Figure 7C**). However, the pattern of change in plasma EV-markers were 535 not consistent across the different isolation methods (**Figure 7C**). Hierarchical clustering of 536 the plasma EV marker response at the time of presentation with MI showed method-537 dependent clustering. Similarly, cell associated markers on plasma EV were differentially 538 enriched following MI (**Figure 7C**). Once again, unbiased clustering showed method-539 dependent groupings. Together these data suggest that changes in plasma-EV protein are 540 influenced by the choice of plasma EV isolation method following MI in isolation and when 541 clustered together.

543 Plasma EV sphingolipidomic profiles are altered following MI and influenced by the isolation 544 method

545 Next, we profiled EV-sphingolipids in the acute phase following MI (calculated as fold over 546 matched follow-up control samples) using the different plasma EV isolation methods. Plasma

21

⁵⁴⁷EV-sphingolipidomic profiles for samples generated by precipitation, acoustic trapping and 548 SEC contained significantly more quantified lipid groups at time of presentation with MI 549 versus samples obtained by UC and immunoaffinity capture ($p<0.01$, all). We ranked plasma ⁵⁵⁰EV-lipid profiles based on their overall abundance of lipid groups and found that ceramides 551 were significantly higher in the precipitation isolated plasma EV samples, followed by SEC, 552 acoustic trapping, ultracentrifugation / immunoaffinity capture (p <0.01). Whereas the 553 sphingomyelins were significantly higher in the precipitation group versus all other isolation 554 methods (p<0.001) (**Figure 7D**). The clustered plasma EV-sphingolipid profile following MI 555 was influenced by the choice of isolation method. Several ceramides and sphingomyelins 556 were significantly higher in the plasma EV isolated by precipitation or acoustic trapping 557 compared to UC (**Supplemental Figure 8**). In addition, the fold increase of Cer(d18:1/22:0), 558 SM(d18:1/18:1) and sphinganine (d18:0) in plasma EV isolated by precipitation at time of 559 presentation vs. 1-month follow up significantly correlated with the infarct size of the patients 560 at 6-months post-MI ($R^2 = 0.91$ p=0.01, $R^2 = 0.78$ p=0.05 and $R^2 = 0.78$ p=0.05, respectively) ⁵⁶¹(**Supplemental Figure 9**). This result further confirmed that plasma EV isolation methods, 562 using targeted sphingolipidomic methods, are associated with unique method dependent 563 profiles in patients following MI.

564

565 Integrated-omics comparison of plasma EV isolation methods in MI patients

⁵⁶⁶Finally, we integrated all the acquired plasma EV data from the MI patients in the acute 567 presentation and follow-up time points. A principal component analysis was constructed to 568 assess if the plasma EV profile at time of presentation differed from follow-up using a 95% 569 confidence level. Integrated analysis showed that plasma EV profiles were only 570 distinguishable at time of presentation with MI for precipitation and acoustic trapping, but not 571 for those plasma EV isolated by UC, SEC and immunoaffinity capture (Figure 8). These 572 findings indicate that different plasma EV isolation methods influence the diagnostic potential 573 of plasma liberated EV following MI when multiple datasets are integrated to determine 574 plasma EV profiles for potential panel biomarker discovery.

⁵⁷⁵**Discussion**

576 Plasma EV-cargo may provide unparalleled insight into tissue homeostasis and pathological 577 processes to facilitate identification of patients for focused therapies, but the methods to 578 isolate plasma EV may impact the EV characteristics. Here, we found that; (I) the choice of 579 plasma EV isolation method affected the plasma EV concentration, sphingolipid and 580 proteomic profile, (II) but the five different plasma EV isolation methods shared a common ⁵⁸¹EV protein and sphingolipid profile. (III) Plasma EV isolation by immunoaffinity capture using 582 anti-CD9, -CD63 and -CD81 coated antibody beads with the current protocol yields a similar 583 profile to IgG control beads. (IV) The isolation method affected the ability to detect 584 alterations in plasma EV sphingolipids and proteins in MI patients and (V) their association 585 with infarct size determined by cardiac MRI 6 months post-MI. For example, the plasma EV 586 concentration at time of presentation obtained using UC provides prognostic information, but 587 this method is less suitable as a tool to generate EV with higher purity for use in mechanistic 588 studies.

589

590 Previous studies have sought to determine the influence of plasma EV isolation methods, 591 but have often focused on comparing the net influence on the EV-proteome [3, 16, 17, 43] or ⁵⁹²RNA profiles [16] after isolation. These approaches can neglect the increased dimensionality 593 of EV components, which carry numerous biologically active molecules such as proteins, 594 lipids, RNA/DNA and metabolites. Furthermore, there is varied assessment of 595 contaminations in EV preparations for use in 'omics' studies, which may mask or skew the 596 interpretation of datasets. The approach employed here utilizes the same independent 597 biological replicates across multiple methods for plasma EV isolation and characterization, in 598 conjunction with a control PBS/vehicle sample or an IgG for immunoaffinity capture beads. ⁵⁹⁹Here, the repeated analysis of the same plasma samples across multiple methods has ⁶⁰⁰enabled individual biological variability and potential plasma EV isolation irregularities to be 601 explored. By using individual and integrated analysis, we showed that each method of 602 plasma EV isolation was internally consistent; in so much that the samples clustered

23

603 according to their isolation method in unsupervised hierarchical clustering and principal 604 component analysis of all the acquired data.

⁶⁰⁶Consistent with previous reports, our plasma EV-proteome was dependent on the plasma ⁶⁰⁷EV isolation method [16, 17]. However, our data shows that there are common plasma 608 proteins, such as albumin and apolipoproteins ApoA-I and ApoB, present in all five isolation ⁶⁰⁹methods tested, with significant similarities to archived EV-databases [31-33] and published 610 studies [16, 17, 31]. In particular, the plasma EV-proteome indicated that UC/SEC cluster 611 together based on the top 30 protein groups quantified, due to higher quantities of 612 fibrinogens and immunoglobulins compared to the other methods. This is, potentially, a 613 methodological constraint of employing untargeted mass spectrometry on plasma EV, which 614 favors the most abundant peptides.

616 To better determine the protein profile of known plasma EV markers and cell associated 617 markers, we utilized a high throughput EV-Array [50] following plasma EV isolation from the 618 five different methods. We found that CD9 and CD81 were the most abundant in plasma EV 619 derived by UC versus precipitation and SEC in healthy volunteers. Additionally, we found 620 that cell-associated markers such as CD41 (platelets) and CD16 (immune cells) were 621 enriched in UC and precipitation compared to other methods only in healthy volunteers. This 622 high throughput antibody EV-Array circumvents issues of non-EV associated protein and 623 lipid contaminants in plasma EV preparations. However, the five different plasma EV 624 isolation methods used here may have influenced the EV-protein corona. Proteins such as 625 albumin and apolipoproteins (ApoA-I, ApoB, ApoC-III and ApoE) show an association with 626 the surface of EV [45], which may influence antibody mediated binding to the array or 627 subsequent detection of EV-associated proteins in this sandwich ELISA like technique. 628 Protein coronas found on EV are affected by the isolation method [45] and our data shows 629 that the plasma EV-proteome and EV-Array acquired data are also influenced by the 630 isolation method. Indeed, our western blot and proteomic data reported considerable

24

631 variation in the amount of albumin across the methods, which is a predominant protein in the ⁶³²EV protein corona. In particular, precipitation isolated preparations was associated with 633 lower albumin, which could be due to the presence of PEG and high salt concentrations in 634 the isolation buffer that might be expected to influence albumin associations with the EV 635 protein corona. The temporal dynamics of the EV-protein and possibly EV-lipid corona are 636 poorly understood, and further elucidation of these interactions will be essential to 637 understand the data from these preparations.

638

639 Immunoaffinity based methods, such as magnetic and polystyrene bead conjugations to 640 specific antibodies, such as tetraspanins (CD9, CD63 and CD81), have been heralded as an 641 important advancement in the capture of highly pure EV populations from the plasma. 642 Immunoaffinity based methods could circumvent issues of lipoprotein and protein 643 contamination in plasma EV yields, which are common in methods that use EV physical 644 characteristics such as size and density for isolation such as UC and SEC [16, 46]. To the 645 best of our knowledge this is the first study to compare magnetic beads coated with 646 antibodies for tetraspanins (CD9, CD63 and CD81) with a matched IgG control for plasma ⁶⁴⁷EV isolation, using detailed integrated analyses. The plasma EV-profile of proteins and lipids 648 for the immunoaffinity beads and matched IgG control was similar by Western blot, EV-649 protein-array, the number of peptides groups in proteomic profiles, GO pathway analysis and 650 targeted sphingolipidomics. TEM imaging of IgG beads showed no visible EV-like particles 651 or membranous structures, indicative of whole or sheared EV-particles, captured to the bead 652 surface. However, we hypothesize that soluble non-EV-associated proteins (such as C3, ⁶⁵³A2M, ALB and fibrinogens A and B) and lipids (such as ApoB, ApoE and ApoA-I) are 654 interacting with IgG beads, which have become associated with EV-profiles in omics studies 655 and in archived databases [31-33]. Studies using less complicated matrices, like conditioned 656 cell culture media, show a more robust distinction between anti-CD9, CD63 and CD81 beads 657 versus IgG control beads [8, 47], indicating that the similarity between tetraspanin and IgG 658 antibody beads here might be matrix specific. Future plasma EV studies using antibody-

25

659 bead isolation should include a matched IgG control per characterisation when using omic-

660 approaches

662 Having determined plasma EV isolations method similarities and differences on the EV-663 characteristics and cargo in healthy volunteers, we assessed the influence of plasma EV 664 isolation methods in a clinical situation where plasma EV number and composition are 665 altered. We have previously shown that plasma EV are altered following MI to mediate long 666 range signalling and induce the mobilization of splenic-neutrophils, splenic-monocytes and 667 orchestrate their transcriptional programming [5, 6]. The choice of plasma EV isolation ⁶⁶⁸method determined whether there was a higher concentration of EV immediately following ⁶⁶⁹MI compared to a 1-month follow-up control sample from the same patients. The new data 670 here support our previous observations that the concentration of plasma EV isolated by UC 671 from the time of presentation with MI correlates with the infarct size [5]. However, plasma EV 672 concentrations derived from the other isolation methods in the same patients did not 673 associate with infarct size. One possible explanation is the modest sample size utilised in 674 this multi-method comparison $(N=6)$, which is smaller than those utilised by us in previous 675 publications $(N=15-22)$ [5, 6].

677 Plasma EV sphingolipids are predictive of MI [3]. However, the influence of plasma EV 678 isolation methods on the plasma EV-sphingolipidomic profile were not reported. We found a 679 distinct sphingolipid profile between the plasma EV isolation methods. Precipitation-based ⁶⁸⁰EV isolation yields a significantly higher lipid content, principally due to higher proportions of 681 sphingomyelins and ceramides. Sphingomyelins are found in cell membranes and 682 associated with high- and low-density lipoproteins [48, 49]. The high presence of 683 sphingomyelins and ceramide in the plasma EV profile of the precipitation-based method is 684 likely due to the co-isolation of lipoproteins. PEG-based solutions co-isolate lipoproteins [56]. ⁶⁸⁵Lipoproteins contain ApoA-I and ApoB, which were higher in plasma EV derived by 686 precipitation-based isolation when compared to the other methods by Western blot.

26

687 Lipoproteins can also masquerade as EV-like particles in dynamic light scattering in 688 techniques such as NTA [12]. Precipitation isolated plasma EV had the highest 689 concentration of particles / mL when compared to other methods. EV Cer(d18:1/20:0) only 690 showed elevation in precipitation-based isolation compared other methods. Similarly, 691 precipitation isolated EV showed sphinganine(d18:0) correlated with infarct size at 6-months, 692 but this was not the case for the other methods. Analysis of plasma EV-sphingolipid remains 693 challenging due to constraints due to lipoparticle remnants [57]; however we show here for 694 the first time there are common sphingolipids for different plasma EV isolation methods. In 695 particular, plasma EV-protein and EV-sphingolipids clustered uniquely based on the isolation ⁶⁹⁶method, which may impact plasma EV diagnostics where a panel of proteins and 697 sphingolipids are used for differentiation of clinical disease or outcome.

699 In summary, our data show that the choice of plasma EV isolation method influences the 700 concentration of plasma EV, the EV-proteome and EV-sphingolipid profile in healthy 701 volunteers and MI patients, where methodological differences determined associations with 702 infarct size. Precipitation based plasma EV isolation gives the highest particle concentration 703 and enriches for more sphingolipids, but co-isolate large quantities of apolipoproteins. In 704 addition, immunoaffinity capture by using antibodies against tetraspanins yields similar EV-705 protein and EV-sphingolipid profiles to IgG control beads. Unbiased integrated analysis 706 shows that plasma EV isolation methods cluster independently, but despite the selection 707 predispositions imposed by each method, a core of EV associated proteins and lipids was 708 detectable using all the approaches.

⁷⁰⁹**Acknowledgments**

710 DP acknowledges his funding from the Department of Pharmacology, the Alison Brading 711 Memorial Fund Lady Margaret Hall, the Clarendon Fund provided by the University of Oxford 712 and the Medical Research Council (MR/N013468/1). NA and RC acknowledge support by 713 research grants from the British Heart Foundation (BHF) Centre of Research Excellence, 714 Oxford (NA and RC: RE/13/1/30181 and RE/18/3/34214); British Heart Foundation Project 715 Grant (NA and RC: PG/18/53/33895); the Tripartite Immunometabolism Consortium, Novo 716 Nordisk Foundation (RC: NNF15CC0018486); Oxford Biomedical Research Centre (BRC); 717 Nuffield Benefaction for Medicine and the Wellcome Institutional Strategic Support Fund 718 (ISSF) (NA) and a Health Research Bridging Salary Scheme (HRBSS) to N.A. BZ work was 719 supported by funding from the European Union's Horizon 2020 Research and Innovation 720 Program under Marie Sklodowska-Curie Grant Agreement 812890, ArthritisHeal. The views 721 expressed are those of the author(s) and not necessarily those of the National Health 722 Service, the National Institutes of Health Research or the Department of Health

723

⁷²⁴**Declaration statement**

 725 The Author(s) declare(s) that there is no conflict of interest.

28

⁷²⁶**References**

⁷²⁷1. de Miguel Pérez, D., et al., Extracellular vesicle-miRNAs as liquid biopsy biomarkers 728 for disease identification and prognosis in metastatic colorectal cancer patients. Sci Rep, 729 2020. 10(1): p. 3974.

⁷³⁰2. Dong, L., et al., Circulating Long RNAs in Serum Extracellular Vesicles: Their

731 Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer.

732 Cancer Epidemiol Biomarkers Prev, 2016. 25(7): p. 1158-66.

⁷³³3. Burrello, J., et al., Sphingolipid composition of circulating extracellular vesicles after 734 myocardial ischemia. Sci Rep, 2020. 10(1): p. 16182.

⁷³⁵4. Kalani, M.Y.S., et al., Extracellular microRNAs in blood differentiate between 736 ischaemic and haemorrhagic stroke subtypes. J Extracell Vesicles, 2020. 9(1): p. 1713540.

⁷³⁷5. Akbar, N., et al., Endothelium-derived extracellular vesicles promote splenic 738 monocyte mobilization in myocardial infarction. JCI Insight, 2017. 2(17).

⁷³⁹6. Akbar, N., et al., Rapid neutrophil mobilisation by VCAM-1+ endothelial extracellular 740 vesicles. Cardiovasc Res, 2022.

741 7. Evander, M., et al., Non-contact acoustic capture of microparticles from small plasma 742 volumes. Lab Chip, 2015. 15(12): p. 2588-96.

⁷⁴³8. Kowal, J., et al., Proteomic comparison defines novel markers to characterize ⁷⁴⁴heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A, 745 2016. 113(8): p. E968-77.

746 9. Onódi, Z., et al., Isolation of High-Purity Extracellular Vesicles by the Combination of 747 Iodixanol Density Gradient Ultracentrifugation and Bind-Elute Chromatography From Blood 748 Plasma. Front Physiol, 2018. 9: p. 1479.

⁷⁴⁹10. Nordin, J.Z., et al., Ultrafiltration with size-exclusion liquid chromatography for high

750 yield isolation of extracellular vesicles preserving intact biophysical and functional properties.

751 Nanomedicine, 2015. 11(4): p. 879-83.

752 11. Geyer, P.E., et al., Plasma Proteome Profiling to detect and avoid sample-related 753 biases in biomarker studies. EMBO Mol Med, 2019. 11(11): p. e10427.

29

754 12. Brennan, K., et al., A comparison of methods for the isolation and separation of 755 extracellular vesicles from protein and lipid particles in human serum. Scientific Reports, 756 2020. 10(1): p. 1039.

757 13. Van Deun, J., et al., The impact of disparate isolation methods for extracellular 758 vesicles on downstream RNA profiling. J Extracell Vesicles, 2014. 3.

⁷⁵⁹14. Thery, C., et al., Minimal information for studies of extracellular vesicles 2018

⁷⁶⁰(MISEV2018): a position statement of the International Society for Extracellular Vesicles and

761 update of the MISEV2014 guidelines. J Extracell Vesicles, 2018. 7(1): p. 1535750.

762 15. Tian, Y., et al., Quality and efficiency assessment of six extracellular vesicle isolation 763 methods by nano-flow cytometry. J Extracell Vesicles, 2020. 9(1): p. 1697028.

⁷⁶⁴16. Veerman, R.E., et al., Molecular evaluation of five different isolation methods for 765 extracellular vesicles reveals different clinical applicability and subcellular origin. Journal of

766 Extracellular Vesicles, 2021. 10(9): p. e12128.

767 17. de Menezes-Neto, A., et al., Size-exclusion chromatography as a stand-alone 768 methodology identifies novel markers in mass spectrometry analyses of plasma-derived 769 vesicles from healthy individuals. J Extracell Vesicles, 2015. 4: p. 27378.

770 18. Gidlöf, O., et al., Proteomic profiling of extracellular vesicles reveals additional 771 diagnostic biomarkers for myocardial infarction compared to plasma alone. Sci Rep, 2019. 772 9(1): p. 8991.

773 19. Askeland, A., et al., Mass-Spectrometry Based Proteome Comparison of ⁷⁷⁴Extracellular Vesicle Isolation Methods: Comparison of ME-kit, Size-Exclusion 775 Chromatography, and High-Speed Centrifugation. Biomedicines, 2020. 8(8): p. 246.

776 20. Palviainen, M., et al., Extracellular vesicles from human plasma and serum are 777 carriers of extravesicular cargo-Implications for biomarker discovery. PLoS One, 2020. 778 15(8): p. e0236439.

⁷⁷⁹21. Cao, F., et al., Proteomics comparison of exosomes from serum and plasma 780 between ultracentrifugation and polymer-based precipitation kit methods. Electrophoresis, 781 2019. 40(23-24): p. 3092-3098.

30

782 22. Jung, H.H., et al., Cytokine profiling in serum-derived exosomes isolated by different 783 methods. Scientific Reports, 2020. 10(1): p. 14069.

784 23. Stranska, R., et al., Comparison of membrane affinity-based method with size-785 exclusion chromatography for isolation of exosome-like vesicles from human plasma. 786 Journal of Translational Medicine, 2018. 16(1): p. 1.

⁷⁸⁷24. Gutiérrez García, G., et al., Analysis of RNA yield in extracellular vesicles isolated by

788 membrane affinity column and differential ultracentrifugation. PLoS One, 2020. 15(11): p. 789 e0238545.

⁷⁹⁰25. Peterka, O., et al., Lipidomic characterization of exosomes isolated from human 791 plasma using various mass spectrometry techniques. Biochim Biophys Acta Mol Cell Biol 792 Lipids, 2020. 1865(5): p. 158634.

⁷⁹³26. Shtam, T., et al., Evaluation of immune and chemical precipitation methods for 794 plasma exosome isolation. PLoS One, 2020. 15(11): p. e0242732.

795 27. Welton, J.L., et al., Ready-made chromatography columns for extracellular vesicle 796 isolation from plasma. J Extracell Vesicles, 2015. 4: p. 27269.

797 28. Thompson, A.G., et al., CSF extracellular vesicle proteomics demonstrates altered 798 protein homeostasis in amyotrophic lateral sclerosis. Clin Proteomics, 2020. 17: p. 31.

⁷⁹⁹29. Subedi, P., et al., Comparison of methods to isolate proteins from extracellular 800 vesicles for mass spectrometry-based proteomic analyses. Anal Biochem, 2019. 584: p. 801 113390.

802 30. Mi, H., et al., PANTHER version 14: more genomes, a new PANTHER GO-slim and 803 improvements in enrichment analysis tools. Nucleic Acids Res, 2019. 47(D1): p. D419-D426.

⁸⁰⁴31. Kim, D.K., et al., EVpedia: an integrated database of high-throughput data for 805 systemic analyses of extracellular vesicles. J Extracell Vesicles, 2013. 2.

⁸⁰⁶32. Kalra, H., et al., Vesiclepedia: a compendium for extracellular vesicles with 807 continuous community annotation. PLoS Biol, 2012. 10(12): p. e1001450.

⁸⁰⁸33. Simpson, R.J., H. Kalra, and S. Mathivanan, ExoCarta as a resource for exosomal 809 research. J Extracell Vesicles, 2012. 1.

31

833 43. Gidlof, O., et al., Proteomic profiling of extracellular vesicles reveals additional 834 diagnostic biomarkers for myocardial infarction compared to plasma alone. Sci Rep, 2019. 835 9(1): p. 8991.

836 44. Bæk, R. and M.M. Jørgensen, Multiplexed Phenotyping of Small Extracellular 837 Vesicles Using Protein Microarray (EV Array). Methods Mol Biol, 2017. 1545: p. 117-127.

32

838 45. Tóth, E., et al., Formation of a protein corona on the surface of extracellular vesicles

- 839 in blood plasma. J Extracell Vesicles, 2021. 10(11): p. e12140.
- 840 46. Tian, B.M., et al., Human platelet lysate supports the formation of robust human
- 841 periodontal ligament cell sheets. J Tissue Eng Regen Med, 2018. 12(4): p. 961-972.
- 842 47. Mathieu, M., et al., Specificities of exosome versus small ectosome secretion
- 843 revealed by live intracellular tracking of CD63 and CD9. Nat Commun, 2021. 12(1): p. 4389.
- ⁸⁴⁴48. Martínez-Beamonte, R., et al., Sphingomyelin in high-density lipoproteins: structural
- 845 role and biological function. Int J Mol Sci, 2013. 14(4): p. 7716-41.
- 846 49. Sódar, B.W., et al., Low-density lipoprotein mimics blood plasma-derived exosomes
- 847 and microvesicles during isolation and detection. Sci Rep, 2016. 6: p. 24316.
- 848 50. Izzo, C., F. Grillo, and E. Murador, Improved method for determination of high-
- 849 density-lipoprotein cholesterol I. Isolation of high-density lipoproteins by use of polyethylene
- 850 glycol 6000. Clin Chem, 1981. 27(3): p. 371-4.
- 851 51. Simonsen, J.B., What Are We Looking At? Extracellular Vesicles, Lipoproteins, or
- 852 Both? Circ Res, 2017. 121(8): p. 920-922.

⁸⁵⁴**Figures**

⁸⁵⁵**Figure 1: A methodological overview**. Platelet poor plasma was obtained from healthy 856 volunteers (n=4) and patients presenting with myocardial infarction (MI) (n=6) (and from the 857 same patients 1-month post-MI) and plasma extracellular vesicles (EV) isolated using five 858 different methods: ultracentrifugation (UC), precipitation, acoustic trapping, size exclusion 859 chromatography (SEC) and immunoaffinity capture with a matched vehicle phosphate 860 buffered saline (PBS) or IgG control. The plasma EV were analyzed using Nanoparticle 861 Tracking Analysis, protein concentration, Western blot, transmission electron microscopy, a 862 targeted EV-protein array for EV-markers CD9, CD63, CD81, ALIX, TSG101, flotillin, 863 Annexin V and 18 other cell associated markers, untargeted proteomics (LC-MS/MS) and 864 targeted sphingolipidomics (LC-MS/MS). The data were analyzed in insolation and following 865 integrated hierarchical clustering and principal component analysis.

⁸⁶⁷**Figure 2: Plasma EV characterization using different isolation methods. (A)** Total 868 plasma extracellular vesicles (EV) / mL concentrations and (B) size and concentration 869 distribution profiles were obtained by Nanoparticle Tracking Analysis (NTA) using 870 ultracentrifugation (UC), precipitation, acoustic trapping, size exclusion chromatography 871 (SEC) and immunoaffinity capture ($n=4$). Values are presented as a delta compared to a 872 vehicle control or IgG control. Scale is logarithmic. **(C)** Protein concentration of plasma EV 873 using UC, precipitation, acoustic trapping, SEC and immunoaffinity capture $(n=4)$. Values 874 are presented as a delta compared to a vehicle control or IgG control. **(D)** Western blot of 875 plasma EV derived from UC, precipitation, acoustic trapping, SEC and immunoaffinity 876 capture versus controls using EV markers ALIX and CD63, lipoprotein contaminants 877 apolipoprotein B (ApoB), and apolipoprotein A-I (ApoA-I), plasma contaminant albumin and 878 cellular contaminant histone H3. Endothelial cell EV and Peripheral blood mononuclear cells ⁸⁷⁹(PBMCs) were used for H3 positive controls. **(E-J).** Transmission electron microscopy (TEM) 880 images of isolated plasma EV from UC, precipitation, acoustic trapping, SEC and 881 immunoaffinity capture versus controls. Each sub panel contains a zoomed-in image (left

34

882 image), an overview image (top right) and a control vehicle image (bottom right). For the 883 immunoaffinity bead capture images, the red arrows indicate EV particles. The scale bar is 884 200 nm for the zoomed images surrounded by a dashed line and 1000 nm for the overview ⁸⁸⁵images and **J**. Values in **A** and **C** are group average ± standard deviation (SD). Data are 886 group average \pm standard deviation (SD) (n=6).

887 Data was analyzed by one-way ANOVA with post-hoc Bonferroni correction. *** p<0.001.

888

⁸⁸⁹**Figure 3: Heatmap of plasma EV derived from different isolation methods using the** ⁸⁹⁰**EV- protein-Array.** The heatmap contains extracellular vesicles (EV) markers CD9, CD81, 891 CD63, ALIX, TSG101, Flotillin 1 and Annexin V for ultracentrifugation (UC), precipitation, 892 acoustic trapping, size exclusion chromatography (SEC) and immunoaffinity capture, lipid 893 contaminants apolipoprotein H (ApoH) and apolipoprotein E (ApoE) and cell associated 894 markers. Values are presented as a delta compared to a vehicle control or IgG control and 895 are log normalized (n=4 per isolation method). Data was analyzed by Krusalski-Wallis test 896 with post-hoc Bonferroni correction. *p<0.05, ***p<0.001.

⁸⁹⁸**Figure 4: Proteomic comparison of plasma EV isolation methods. (A)** The number of 899 protein groups quantified by unbiased proteomics for plasma extracellular vesicles (EV) 900 derived by: ultracentrifugation (UC), precipitation, acoustic trapping, size exclusion 901 chromatography (SEC) and immunoaffinity capture, versus control vehicle (PBS) or an IgG 902 control. Protein groups were only included as quantified if they had ≥2 unique peptides. 903 (n=3-4). One-way ANOVA with post-hoc Bonferroni correction. Data are group averages \pm 904 standard deviation (SD). *p<0.05, ***p<0.001. **(B)** A heatmap of the top 30 quantified protein 905 groups across all isolation methods. Values from control samples were subtracted to 906 account for background and the values were log normalised. Hierarchical clustering of the 907 isolation methods was conducted using a complete clustering method. $(n=3-4)$.

908

35

⁹⁰⁹**Figure 5: Sphingolipidomic analysis of plasma EV from different isolation methods.** ⁹¹⁰**(A)** Number of sphingolipids quantified in plasma extracellular vesicles (EV) isolated by 911 ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography ⁹¹²(SEC) and immunoaffinity capture and subjected to targeted sphingolipid analysis versus 913 control vehicle (PBS) or an IgG control. Data are group averages \pm standard deviation (SD) 914 and were analysed by One-way ANOVA with post-hoc Bonferroni correction. ***p<0.001. ⁹¹⁵(n=4) **(B)** Heat map of plasma EV sphingolipids. Values from control samples were 916 subtracted to account for background and the values were log normalised. Hierarchical 917 clustering of the isolation methods was conducted using a complete clustering method. $(n=3-1)$ 918 4). Data were analysed by Krusalski-Wallis test with post-hoc Bonferroni correction.

919

⁹²⁰**Figure 6: Principal component analysis of plasma EV characteristics following data** ⁹²¹**integration. (A)** A principal component (PC) analysis of plasma extracellular vesicles (EV) 922 isolated by ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion 923 chromatography (SEC) and immunoaffinity capture: including plasma EV concentration, 924 protein concentration, EV-protein-Array, proteomics and sphingolipidomics. The integrated 925 data was condensed to PC1 and PC2. **(B)** A heatmap with the various principal components 926 to compare the different isolation plasma EV isolation methods. Hierarchical clustering of the 927 isolation methods was conducted using a complete clustering method. $(n=3-4)$.

928

⁹²⁹**Figure 7: Plasma EV analysis using different isolation methods in patients following** ⁹³⁰**presentation with myocardial (MI) infarction compared to samples from the same** ⁹³¹**patients after a 1-month follow up. (A)** Comparison of concentration and size-distribution 932 profile by Nanoparticle Tracking Analysis of plasma extracellular vesicles (EV) from patients 933 following presentation with MI and after a 1-month follow up using: ultracentrifugation (UC), 934 precipitation, acoustic trapping, size exclusion chromatography (SEC) and immunoaffinity 935 capture (n=6 per timepoint). Data are group average ± standard deviation (SD). Paired T-936 test analysis *p<0.05. **(B)** A Pearson correlation analysis of plasma EV / mL derived from

36

937 each isolation method at time of presentation vs. the infarct size determined by cardiac MRI 938 using late gadolinium enhancement 6-months post-infarct (n=5). **(C)** Heatmap of plasma EV-939 Array analysis. The top section of the heatmap contains the different EV markers CD9, 940 CD81, CD63, ALIX, TSG101, Flotillin 1 and Annexin V. Values are presented as fold over 941 the respective matched follow up control sample. **(D)** Heatmap showing the plasma EV 942 sphingolipidomic profiles in MI patents at presentation versus a 1-month follow up for UC, 943 precipitation, acoustic trapping, SEC and immunoaffinity capture. Values are presented as 944 fold over the respective matched follow up.

⁹⁴⁶**Figure 8: Principal component analysis of integrated plasma EV characterisation at** ⁹⁴⁷**time of presentation with myocardial infarction (MI) vs. 1-moth follow-up in the same** ⁹⁴⁸**patients using different plasma EV isolation methods.** A principal component (PC) 949 analysis of plasma EV isolated by ultracentrifugation (UC), precipitation, acoustic trapping, 950 size-exclusion chromatography (SEC) and immunoaffinity capture from patients presenting 951 with MI versus a 1-month follow up control. Plasma EV characteristics include including 952 plasma EV concentration, protein concentration, EV-protein-Array and sphingolipidomics. 953 The integrated data was condensed to PC1 and PC2. $(n=5-6)$. The eclipses indicate the 954 95% confidence interval.

955

⁹⁵⁶**Tables**

⁹⁵⁷**Table 1: Nanoparticle Tracking Analysis showing the mean and median size of** 958 **plasma- EV** isolated by ultracentrifugation (UC), precipitation, acoustic trapping, size-959 exclusion chromatography (SEC). Immunoaffinity capture can not be acquired. Data are 960 group averages \pm standard deviation (SD) and were analyzed by One-way ANOVA with 961 post-hoc Bonferroni correction. ***p<0.001. (n=4).

 $\frac{1}{2}$

⁹⁶³**Table 2: Clinical characteristics of the MI patients.** Age, sex (M/F), glucose, white blood 964 cells counts, troponin peak, cholesterol, diabetes status, smoker status, infarct size 965 determined by late gadolinium enhancement MRI 6 months post-AMI and left ventricle 966 ejection fraction (LVEF %) 6 moths post-MI. Data are group averages ± standard deviation 967 (SD) (n=6).

38

⁹⁶⁸**Supplemental Figures**

⁹⁶⁹**Supplemental Figure 1: The ratio of plasma extracellular vesicles (EV) to protein** ⁹⁷⁰**concentration per isolation method:** ultracentrifugation (UC), precipitation, acoustic 971 trapping, size-exclusion chromatography (SEC) and immunoaffinity capture. EV are 972 expressed as per mL and protein concentration is expressed ug. Values are expressed as 973 delta over phosphate buffer solution (PBS) control or IgG control. Data are group averages \pm 974 standard deviation (SD) (n=4). One-way ANOVA with post-hoc Bonferroni correction. ⁹⁷⁵**p<0.01, ***p<0.001.

⁹⁷⁷**Supplemental Figure 2: Venn diagram of quantified protein groups in different plasma** ⁹⁷⁸**extracellular vesicle (EV) isolation methods:** ultracentrifugation (UC), precipitation, 979 acoustic trapping, size-exclusion chromatography (SEC) and immunoaffinity capture. 980 Quantified protein groups within a method were pooled after subtraction of phosphate buffer 981 solution (PBS) control or IgG control. Protein groups that had more than 1 repeat within a 982 method were included in the Venn diagram.

⁹⁸⁴**Supplemental Figure 3: Gene Ontology analysis of plasma extracellular vesicle (EV)** ⁹⁸⁵**isolation method proteomics:** ultracentrifugation (UC), precipitation, acoustic trapping, 986 size-exclusion chromatography (SEC) and immunoaffinity capture. **(A)** Quantified protein 987 groups were expressed as delta over phosphate buffer solution (PBS) control or IgG control. ⁹⁸⁸Quantified protein groups that appeared more than once per method were included in the 989 Gene Ontology (GO) analysis. The GO cellular components associated with each method 990 were ranked based on the false discovery rate (FDR) and the top five were included in the 991 tables. In addition, the GO enrichment scores were plotted against the false discovery rate p-992 values in the scatterplot. **(B)** The overlap between quantified protein groups per plasma EV 993 isolation method and published EV proteomics databases EVpedia, Exocarta and 994 Vesiclepedia. The table contains the percentage of overlapping protein groups vs. total 995 protein groups per isolation method, with a p-value calculated by fisher-exact test.

39

996

⁹⁹⁷**Supplemental Figure 4: The overlap between the number of quantified protein groups** ⁹⁹⁸**per plasma extracellular vesicle** (**EV) isolation method and published plasma EV** ⁹⁹⁹**proteomic datasets.** Quantified protein groups within a method were pooled after 1000 subtraction of phosphate buffer solution (PBS) control or IgG control. Protein groups that had 1001 more than 1 repeat within a method were included. Plasma EV-proteomes determined by 1002 ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography ¹⁰⁰³(SEC) and immunoaffinity capture were compared with published EV proteomic datasets. ¹⁰⁰⁴The overlap of protein groups between each method were compared and listed out of the 1005 total protein groups quantified.

¹⁰⁰⁷**Supplemental Figure 5: Venn diagram showing the overlap between quantified** ¹⁰⁰⁸**sphingolipids in different plasma extracellular vesicles (EV) isolation methods:** 1009 ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography ¹⁰¹⁰(SEC) and immunoaffinity capture. Sphingolipids within a method were pooled after 1011 subtraction of phosphate buffer solution (PBS) control or IgG control. Sphingolipids that had 1012 more than 1 repeat within a method were included in the Venn diagram.

¹⁰¹⁴**Supplemental Figure 6: Scree plots of each principal component following the** ¹⁰¹⁵**integrated data analysis of plasma extracellular vesicle (EV) isolated with the different** ¹⁰¹⁶**methods:** ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion 1017 chromatography (SEC) and immunoaffinity capture. Data from the acquired unbiased 1018 proteomics, targeted sphingolipidomics, EV-Array analysis and concentration/size analysis 1019 was pooled for each isolation method. Principal components were generated with the R-1020 package *Factoextra* and *FactoMineR*. Each scree plot indicates the percentage of variance 1021 explained for the principal component and the top 30 drivers for the principal component. 1022 Data was labelled based on the origin; Lipid indicates data from the targeted sphingolipid

40

1023 data, EV indicates data from the EV-protein-array and unlabeled was selected for data from 1024 the proteomics.

¹⁰²⁶**Supplemental Figure 7: Plasma extracellular vesicle (EV) concentration and size** ¹⁰²⁷**characteristics after isolation from myocardial infarction (MI) patients at time of** ¹⁰²⁸**presentation and one month follow up. (A)** The variance of plasma EV concentration 1029 isolated by each method measured by Nanoparticle Tracking Analysis (NTA). The variance 1030 was calculated by relative standard deviation over three different measurements. Values are 1031 expressed as delta over phosphate buffer solution (PBS) control or IgG control. **(B)** The 1032 average size of the isolated plasma EV for each method at time of presentation vs. follow up ¹⁰³³measured by NTA. Immunoaffinity capture can not be acquired. **(C)** Size distribution profiles 1034 of the plasma EV from MI patients at time of presentation and one month follow up. 1035 Immunoaffinity capture can not be acquired. Data are group averages \pm standard deviation ¹⁰³⁶(SD) (n=12 for **A**, n=6 for **B,** n=6 per time point for **C**). One-way ANOVA with post-hoc ¹⁰³⁷Bonferroni correction. *p<0.05 for **A** and **B**.

¹⁰³⁹**Supplemental Figure 8: Sphingolipid concentrations of plasma extracellular vesicles** ¹⁰⁴⁰**(EV) isolated by different methods:** ultracentrifugation (UC), precipitation, acoustic 1041 trapping, size-exclusion chromatography (SEC) and immunoaffinity capture. The fold change 1042 in sphingolipid concentration in plasma EV isolated at time of presentation with myocardial 1043 infarction (MI) versus the concentration in plasma EV isolated 1-month post-MI per isolation 1044 method. Data are group averages \pm standard deviation (SD) and were analysed by one-way 1045 ANOVA with post-hoc Bonferroni correction. *p<0.05 and **p<0.01. (n=5-6)

Supplemental Figure 9: Plasma extracellular vesicle (EV) sphingolipid concentration correlation with infarct size. A Pearson correlation analysis was conducted with the the fold change in sphingolipid (**A**: Cer(d18:0/22:0) ; **B**: sphinganine (d18:0) ; **C**: SM(d18:1/18:1) 1050 concentration in plasma EV isolated at time of presentation with myocardial infarction (MI)

- 1051 versus the concentration in plasma EV isolated 1-month post-MI by the precipitation method
- 1052 versus the infarct size determined by cardiac MRI using late gadolinium enhancement 6-
- 1053 months post-infarct $(n=5)$.

Data integration

SEC H

E

IgG control

I

Immunoaffinity

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.12.22273619;](https://doi.org/10.1101/2022.04.12.22273619) this version posted April 16, 2022. The copyright holder for this prep

B

B

All rights reserved. No reuse allowed without permission. (which was not certified by peet teview) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.12.22273619;](https://doi.org/10.1101/2022.04.12.22273619) this version posted April 16, 2022. The copyright holder for this prep

Table 1

Table 2

